目的 研究补阳还五汤治疗帕金森病（Parkinson's disease，PD）的临床疗效。方法 将43例PD患者随机分为治疗组（22例）和对照组（21例）。对照组根据患者病情的需要，酌情给予美多芭、盐酸苯海索、金刚烷胺等治疗，治疗组在西药治疗基础上加服补阳还五汤，每日1剂，分2次口服，共治疗6周。每治疗2周，比较两组患者的改良Hoehn-Yahr分级和统一帕金森病评定量表（unified Parkinson's disease rating scale，UPDRS）评分。结果 治疗2、4、6周末，两组患者改良Hoehn-Yahr分级和UPDRS Ⅲ评分逐渐降低；治疗4、6周末，两组患者改良Hoehn-Yahr分级和UPDRS Ⅲ评分均较入组前显著降低（P＜0.05）。各时点两组患者改良Hoehn-Yahr分级比较，差异均无统计学意义（P＞0.05）；治疗2、4、6周末，治疗组患者UPDRS Ⅲ评分均显著低于对照组（P＜0.05）。结论 补阳还五汤具有良好的抗PD作用，或能加速美多芭的抗PD作用，但具体机制有待进一步研究。
Objective To investigate the clinical effect of Buyang Huanwu Decoction in the treatment of Parkinson's disease (PD). Methods A total of 43 patients with PD were randomly divided into treatment group with 22 patients and control group with 21 patients. The patients in the control group were given Madopar, benzhexol hydrochloride, and amantadine based on their condition, and those in the treatment group were given oral Buyang Huanwu Decoction one dose a day in two divided doses in addition to the Western medicine treatment in the control group. The course of treatment was 6 weeks. The two groups were compared in terms of modified Hoehn-Yahr stage and unified Parkinson's disease rating scale (UPDRS) score every two weeks. Results At the end of weeks 2, 4, and 6 of treatment, both groups had gradual reductions in modified Hoehn-Yahr stage and UPDRS Ⅲ score, and from enrollment to the end of weeks 4 and 6 of treatment, both groups had significant reductions in modified Hoehn-Yahr stage and UPDRS Ⅲ score (P<0.05). There was no significant difference in modified Hoehn-Yahr stage between the two groups at each time point (P>0.05), and at the end of weeks 2, 4, and 6 of treatment, the treatment group had a significantly lower UPDRS Ⅲ score than the control group (P<0.05). Conclusion Buyang Huanwu Decoction has a good anti-PD effect and may accelerate the anti-PD effect of Madopar, but further studies are needed to clarify the specific mechanism.